Article Sidebar

Download
PDF

Main Article Content

Abstract

The synthesis of 10 novel 1,2,4-triazolo[1,5-a]pyrimidine derivatives have been undertaken by involving Biginelli type three components reaction of 1-phenyl-3-aryl-1H-pyrazole-4-carbaldehydes, 3-amino- 1,2,4-triazole and ethyl acetoacetate in DMF. The structure of all the compounds have been established by IR, FT-IR, 1H NMR, 13C NMR, mass spectra and elemental analyses. The antimicrobial activity against S. aureus MTCC-96 (Gram positive), E. coli MTCC-443 (Gram negative) and antifungal activity against A. niger MTCC-282 and C. albicans MTCC-227 at different concentrations using micro-dilution broth method according to NCCLS standards. The antimicrobial activity was compared with ampicillin, chloramphenicol, ciprofloxacin, norfloxacin, nystatin and greseofulvin as standard drugs at same different concentration. The compounds such as A-2, A-4, A-5, A-6, A-8, A-9, A-10 showed moderate antibacterial activity against Staphylococcus aureus (Gram positive) at the concentration of 250, 100, 250, 200, 250, 250, 250 μg/mL while compounds A-3 and A-6 showed remarkable antibacterial activity against Streptococcus pyogenes (Gram positive) at the concentration of 100 μg/mL. Moreover, the compounds A-3 and A-9, found to be potent against Escherichia coli (Gram negative) at the concentration of 62.5, 62.5 (μg/mL) and against Pseudomonas aeruginosa (Gram negative) with the concentration of 100 μg/mL.

Keywords

Biological screening 1,2,4-Triazolo[1,5-a]pyrimidines 3-amino-1,2,4-triazole Biginelli reaction

Article Details

How to Cite
Chauhan, M., Vaghasiya, R., Parekh, H., & Shah, V. (2018). A Rapid One-Pot Synthesis and Biological Evaluation of Novel 1,2,4-Triazolo[1,5-a]-pyrimidines. Asian Journal of Organic & Medicinal Chemistry, 3(3), 116–120. https://doi.org/10.14233/ajomc.2018.AJOMC-P139
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. C. Ainsworth, N.R. Easton, M. Livezey, D.E. Morrison and W.R. Gibson, The Anticonvulsant Activity of 1,2,4-Triazoles, J. Med. Chem., 5, 383 (1962); https://doi.org/10.1021/jm01237a016.
  2. T. Mano, R.W. Stevens, Y. Okumura, M. Kawai, T. Okumura and M. Sakakibara, 5-Lipoxygenase Inhibitors: Convenient Synthesis of 4-[3-(4-Heterocyclylphenylthio)phenyl]-3,4,5,6-tetrahydro-2H-pyran-4-carboxamide Analogues, Bioorg. Med. Chem. Lett., 15, 2611 (2005); https://doi.org/10.1016/j.bmcl.2005.03.041.
  3. B.S. Holla, B. Veerendra, M.K. Shivananda and B. Poojary, Synthesis, Characterization and Anticancer Activity Studies on Some Mannich Bases Derived from 1,2,4-Triazoles, Eur. J. Med. Chem., 38, 759 (2003); https://doi.org/10.1016/S0223-5234(03)00128-4.
  4. C. Dahlof and C. Lines, Rizatriptan: a New 5-HT1B/1D Receptor Agonist for the Treatment of Migraine, Expert Opin. Investig. Drugs, 8, 671 (1999); https://doi.org/10.1517/13543784.8.5.671.
  5. F. Sternfeld, R. Baker, H.B. Broughton, A.R. Guiblin, R.A. Jelley, V.G. Matassa, A.J. Reeve, M.S. Beer, J.A. Stanton, R.J. Hargreaves, S.L. Shepheard, J. Longmore, Z. Razzaque, M.I. Graham, B. Sohal and L.J. Street, The Chemical Evolution of N,N-Dimethyl-2-[5-(1,2,4-triazol-4-yl)-1H-indol-3-yl]ethylamine (L-741,604) and Analogues: Potent and Selective Agonists for 5-HT1D Receptors, Bioorg. Med. Chem. Lett., 6, 1825 (1996); https://doi.org/10.1016/0960-894X(96)00324-1.
  6. P. Ordentlich, Identification of the Antineoplastic Agent 6-Mercapto-purine as an Activator of the Orphan Nuclear Hormone Receptor Nurr1, J. Biochem., 278, 24791 (2003); https://doi.org/10.1074/jbc.M302167200.
  7. M. Hoffmann, M. Chrzanowska, T. Hermann and J. Rychlewski, Modeling of Purine Derivatives Transport across Cell Membranes Based on Their Partition Coefficient Determination and Quantum Chemical Calculations, J. Med. Chem., 48, 4482 (2005); https://doi.org/10.1021/jm0495273.
  8. J. Tani, Y. Yamada, T. Oine, T. Ochiai, R. Ishida and I. Inoue, Studies on Biologically Active Halogenated Compounds. 1. Synthesis and Central Nervous System Depressant Activity of 2-(Fluoromethyl)-3-Aryl-4(3H)-Quinazolinone Derivatives, J. Med. Chem., 22, 95 (1979); https://doi.org/10.1021/jm00187a021.
  9. P. Adnet, P. Lestavel and R. Krivosic-Horber, Neuroleptic Malignant Syndrome, Br. J. Anaesth., 85, 129 (2000); https://doi.org/10.1093/bja/85.1.129.
  10. G. Dorothy, A. Smith and S. Waksman, Tuberculostatic and Tuberculo-cidal Properties of Streptomycin1, J. Bacteriol., 54, 253 (1947).
  11. (a) X.-L. Zhao, Y.-F. Zhao, S.-C. Guo, H.-S. Song, D. Wang and P. Gong, Synthesis and Anti-tumor Activities of Novel [1,2,4]triazolo[1,5-a]pyrimidines, Molecules, 12, 1136 (2007); https://doi.org/10.3390/12051136. (b) G.S. Hassan, M.A. El-Sherbeny, M.B. El-Ashmawy, S.M. Bayomi, A.R. Maarouf and F.A. Badriacd, Synthesis and Antitumor Testing of Certain New Fused Triazolopyrimidine and Triazoloquinazoline Derivatives, Arab. J. Chem., 10, S1345 (2017); https://doi.org/10.1016/j.arabjc.2013.04.002.
  12. T. Saito, T. Obitsu, C. Minamoto, T. Sugiura, N. Matsumura, S. Ueno, A. Kishi, S. Katsumata, H. Nakai and M. Toda, Pyrazolo[1,5-a]pyrimi-dines, Triazolo[1,5-a]pyrimidines and their Tricyclic Derivatives as Corticotropin-Releasing Factor 1 (CRF1) Receptor Antagonists, Bioorg. Med. Chem., 19, 5955 (2011); https://doi.org/10.1016/j.bmc.2011.08.055.
  13. C. Hougaard, S. Hammami, B.L. Eriksen, U.S. Sorensen, M.L. Jensen, D. Strobaek and P. Christophersen, Evidence for a Common Pharmaco-logical Interaction Site on KCa2 Channels Providing Both Selective Activation and Selective Inhibition of the Human KCa2.1 Subtype, Mol. Pharmacol., 81, 210 (2012); https://doi.org/10.1124/mol.111.074252.
  14. S. Uryu, S. Tokuhiro, T. Murasugi and T. Oda, A Novel Compound, RS-1178, Specifically Inhibits Neuronal Cell Death Mediated by b-Amyloid-Induced Macrophage Activation in vitro, Brain Res., 946, 298 (2002); https://doi.org/10.1016/S0006-8993(02)02898-6.
  15. C. Mustazza, M.R.D. Giudice, A. Borioni and F. Gatta, A Novel Compound, RS-1178, Specifically Inhibits Neuronal Cell Death Mediated By b-Amyloid-Induced Macrophage Activation in vitro, Heterocycl. Chem., 38, 1119 (2001); https://doi.org/10.1002/jhet.5570380516.
  16. N. Zhang, S. Ayral-Kaloustian, T. Nguyen, J. Afragola, R. Hernandez, J. Lucas, J. Gibbons and C. Beyer, Synthesis and SAR of [1,2,4]Triazolo-[1,5-a]pyrimidines, A Class of Anticancer Agents with a Unique Mechanism of Tubulin Inhibition, J. Med. Chem., 50, 319 (2007); https://doi.org/10.1021/jm060717i.
  17. L. Havlicek, K. Fuksova, V. Krystof, M. Orsag, B. Vojtesek and M. Strnad, 8-Azapurines as New Inhibitors of Cyclin-Dependent Kinases, Bioorg. Med. Chem., 13, 5399 (2005); https://doi.org/10.1016/j.bmc.2005.06.007.
  18. M.E. Fraley, W.F. Hoffman, R.S. Rubino, R.W. Hungate, A.J. Tebben, R.Z. Rutledge, R.C. McFall, W.R. Huckle, R.L. Kendall, K.E. Coll and K.A. Thomas, Synthesis and Initial SAR Studies of 3,6-Disubsti-tuted Pyrazolo[1,5-a]pyrimidines: A New Class of KDR Kinase Inhibitors, Bioorg. Med. Chem. Lett., 12, 2767 (2002); https://doi.org/10.1016/S0960-894X(02)00525-5.
  19. Q. Chen, X.-L. Zhu, L.-L. Jiang, Z.-M. Liu and G.-F. Yang, Synthesis, Antifungal Activity and CoMFA Analysis of Novel 1,2,4-Triazolo[1,5-a]-pyrimidine Derivatives, Eur. J. Med. Chem., 43, 595 (2008); https://doi.org/10.1016/j.ejmech.2007.04.021.